成功血管内再灌注后辅助溶栓:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入6项随机对照试验共1974例大血管闭塞卒中患者,评估成功血管内取栓后辅助动脉内溶栓的疗效与安全性。结果显示动脉内溶栓显著提高90天极佳功能预后(mRS 0-1)的几率,主要见于前循环,后循环获益不确定,且未增加症状性颅内出血或90天死亡风险。
要点
- 成功取栓后辅助动脉内溶栓可提高90天mRS 0-1的几率(OR=1.47)。
- 前循环获益显著(OR=1.48),后循环获益不确定(OR=1.51,无统计学意义)。
- 阿替普酶与替奈普酶均与良好预后相关,且未增加sICH或死亡风险。
核心结论
- 成功血管内取栓后行动脉内溶栓显著提高90天极佳功能预后几率,尤其前循环卒中。
- 后循环卒中获益不确定,但不同溶栓药物及卒中部位间sICH风险与死亡率无显著差异,支持其安全性。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、ClinicalTrials.gov、Cochrane Library及2025年国际卒中会议摘要(2015年1月至2025年2月)。
- 纳入6项随机对照试验,共1974例大血管闭塞卒中患者,方案注册于PROSPERO(CRD420250651602)。
主要发现
- 主要汇总分析显示动脉内溶栓提高90天mRS 0-1的几率(OR=1.47,95%CI 1.21-1.80,p<0.001)。
- 前循环卒中获益显著(OR=1.48,95%CI 1.18-1.87,p<0.001),后循环无显著获益(OR=1.51,95%CI 0.83-2.74,p=0.18)。
- 阿替普酶与良好预后关联最强(OR=1.94,95%CI 1.31-2.87,p<0.001),替奈普酶次之(OR=1.43,95%CI 1.08-1.89,p=0.01)。
- sICH几率未增加(OR=1.15,95%CI 0.75-1.75,p=0.51),90天死亡率无差异(OR=1.00,95%CI 0.79-1.26,p=0.99)。
- 所有结局的敏感性分析结果一致。
关键数值与推荐
- 主要结局为90天极佳功能预后(mRS=0-1)。
- 次要结局为90天功能独立(mRS=0-2);安全指标包括症状性颅内出血和90天死亡率。
临床怎么用
- 对前循环大血管闭塞且成功再灌注的患者,可考虑辅助动脉内溶栓以改善极佳功能预后。
- 后循环卒中辅助动脉内溶栓的获益尚不明确,需个体化决策。
- 阿替普酶和替奈普酶均可选用,安全性未见显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The efficacy and safety of intra-arterial thrombolysis (IAT) as an adjunct to endovascular thrombectomy (EVT) in large vessel occlusion strokes (LVOS) remain uncertain, with recent randomized controlled trials (RCTs) yielding conflicting results. This meta-analysis aimed to assess the impact of IAT following successful EVT in patients with LVOS. METHODS: A comprehensive search was conducted across PubMed, ClinicalTrials.gov, the Cochrane Library databases, and the International Stroke Conference 2025 abstracts to identify RCTs evaluating IAT following successful EVT from January 2015 to February 2025. The primary outcome was the odds of achieving an excellent functional outcome (defined as a modified Rankin Scale [mRS] = 0-1 at 90 days). Secondary outcomes included 90-day functional independence (mRS = 0-2). Safety measures included symptomatic intracranial hemorrhage (sICH), and mortality at 90 days. The protocol was registered in PROSPERO (CRD420250651602). RESULTS: The primary pooled analysis of 6 RCTs (N = 1,974) showed that IAT significantly increased the likelihood of achieving excellent functional outcome at 90 days (mRS = 0-1: odds ratio [OR] = 1.47, 95% confidence interval [CI] = 1.21-1.80, p < 0.001), with a notable effect in anterior circulation (OR = 1.48, 95% CI = 1.18-1.87, p < 0.001) but not in posterior circulation LVOS (OR = 1.51, 95% CI = 0.83-2.74, p = 0.18). Among thrombolytic drugs, alteplase was most strongly associated with favorable outcomes (mRS = 0-1: OR = 1.94, 95% CI = 1.31-2.87, p < 0.001), followed by tenecteplase (OR = 1.43, 95% CI = 1.08-1.89, p = 0.01). No significant safety concerns were observed, as there was no increase in the odds of sICH (OR = 1.15, 95% CI = 0.75-1.75, p = 0.51) or 90-day mortality (OR = 1.00, 95% CI = 0.79-1.26, p = 0.99). Sensitivity analyses for all outcomes yielded consistent results. INTERPRETATION: IAT following successful EVT significantly enhances the likelihood of achieving an excellent functional outcome, particularly in anterior circulation strokes. Although the benefit in posterior circulation strokes remains uncertain, the lack of significant differences in sICH risk and mortality across thrombolytic drugs and stroke locations support the safety of IAT. ANN NEUROL 2025;98:1299-1314.
引用
- Doheim MF, Mohammaden MH, Jumah A, et al. Adjunctive Thrombolytics After Successful Endovascular Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ann Neurol. 2025. PMID: 40799167. doi:10.1002/ana.70021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。